Synchronous Bilateral Breast Cancer Diagnosed as Invasive Lobular and Invasive Ductal Carcinoma

2014 ◽  
Vol 3 (4) ◽  
pp. 152
Author(s):  
Emrah Çağlar ◽  
Fatma Tuba Kızıltepe ◽  
Zehra Sumru Çoşar ◽  
Elif Aktaş ◽  
Bilgin Kadri Arıbaş ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Synchronous Bilateral Breast Cancer

Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 118-122
Author(s):  
P. F. Escobar ◽  
R. Patrick ◽  
L. Rybicki ◽  
N. Al-Husaini ◽  
C. M. Michener ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Cancer Diagnosis ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Rank Test ◽  
Cancer Data ◽  
Synchronous Bilateral Breast Cancer ◽  
Gynecological Neoplasms

The purpose of this study was to quantify and describe nonmammary neoplasms (n-MN), particularly gynecological neoplasms, in a patient population previously diagnosed with breast cancer. Data were collected prospectively in our institutional review board–approved registry for patients diagnosed with infiltrating breast cancer or ductal carcinoma in situ. Patients who developed a second, n-MN were identified; neoplastic site, time to development after breast cancer, and clinical outcomes were recorded. FIGO stage was recorded for patients who developed a gynecological neoplasm. Synchronous bilateral breast cancer was defined as a second, contralateral diagnosis made within 12 months of the first and, similarly, synchronous n-MN were defined as those identified within 1 year of a breast cancer diagnosis. Outcome curves were generated using the method of Kaplan and Meier, and compared using the log-rank test. Of 4126 patients diagnosed with breast cancer, 3% developed a n-MN, the majority of which were nongynecological and asynchronous to the initial breast cancer diagnosis. Three percent of patients diagnosed with breast cancer were diagnosed with a second, n-MN. Among patients who developed a n-MN, most developed a nongynecological cancer more than 1 year after the initial breast cancer diagnosis, and their outcomes were significantly worse than those patients who did not develop a n-MN.

scholarly journals Unusual Case of Bilateral Breast Cancer: A Pure Encapsulated Papillary Breast Tumor of the Right Breast and a Contralateral Invasive Ductal Carcinoma

2015 ◽  
Vol 04 (02) ◽  
pp. 39-43
Author(s):  
Alberto Testori ◽  
Valentina Errico ◽  
Edoardo Bottoni ◽  
Emanuele Voulaz ◽  
Stefano Meroni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Breast Tumor ◽  
Unusual Case ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
The Right

Expression of Let-7c in invasive ductal carcinoma of breast cancer and its clinical significance

2009 ◽  
Vol 29 (4) ◽  
pp. 400-403
Author(s):  
Shu-rong SHEN ◽  
Jun-yi SHI ◽  
Xian SHEN ◽  
Guan-li HUANG ◽  
Xiang-yang XUE
Keyword(s):  
Breast Cancer ◽  
Clinical Significance ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma

Uncommon Breast Malignancies: Presentation Pattern, Prognostic Issue and Treatment Outcome in an Italian Single Institution Experience

2013 ◽  
Vol 99 (1) ◽  
pp. 39-44
Author(s):  
Claudia Maria Regina Bareggi ◽  
Dario Consonni ◽  
Barbara Galassi ◽  
Donatella Gambini ◽  
Elisa Locatelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Outcome ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Medullary Carcinoma ◽  
Mucinous Carcinoma ◽  
Lymph Node Involvement ◽  
Tubular Carcinoma ◽  
Breast Malignancies

Aims and background Often neglected by large clinical trials, patients with uncommon breast malignancies have been rarely analyzed in large series. Patients and methods Of 2,052 patients diagnosed with breast cancer and followed in our Institution from January 1985 to December 2009, we retrospectively collected data on those with uncommon histotypes, with the aim of investigating their presentation characteristics and treatment outcome. Results Rare histotypes were identified in 146 patients (7.1% of our total breast cancer population), being classified as follows: tubular carcinoma in 75 (51.4%), mucinous carcinoma in 36 (24.7%), medullary carcinoma in 25 (17.1%) and papillary carcinoma in 10 patients (6.8%). Whereas age at diagnosis was not significantly different among the diverse diagnostic groups, patients with medullary and papillary subtypes had a higher rate of lymph node involvement, similar to that of invasive ductal carcinoma. Early stage diagnosis was frequent, except for medullary carcinoma. Overall, in comparison with our invasive ductal carcinoma patients, those with rare histotypes showed a significantly lower risk of recurrence, with a hazard ratio of 0.28 (95% CI, 0.12–0.62; P = 0.002). Conclusions According to our analysis, patients with uncommon breast malignancies are often diagnosed at an early stage, resulting in a good prognosis with standard treatment.

StackBC: Deep learning and transfer learning techniques based stacking approach for accurate Invasive Ductal Carcinoma classification using histology images

2022 ◽  
pp. 1-12
Author(s):  
Amin Ul Haq ◽  
Jian Ping Li ◽  
Samad Wali ◽  
Sultan Ahmad ◽  
Zafar Ali ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Deep Learning ◽  
Transfer Learning ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Early Recognition ◽  
Predictive Performance ◽  
Operating Characteristics ◽  
Data Set ◽  
Learning Techniques

Artificial intelligence (AI) based computer-aided diagnostic (CAD) systems can effectively diagnose critical disease. AI-based detection of breast cancer (BC) through images data is more efficient and accurate than professional radiologists. However, the existing AI-based BC diagnosis methods have complexity in low prediction accuracy and high computation time. Due to these reasons, medical professionals are not employing the current proposed techniques in E-Healthcare to effectively diagnose the BC. To diagnose the breast cancer effectively need to incorporate advanced AI techniques based methods in diagnosis process. In this work, we proposed a deep learning based diagnosis method (StackBC) to detect breast cancer in the early stage for effective treatment and recovery. In particular, we have incorporated deep learning models including Convolutional neural network (CNN), Long short term memory (LSTM), and Gated recurrent unit (GRU) for the classification of Invasive Ductal Carcinoma (IDC). Additionally, data augmentation and transfer learning techniques have been incorporated for data set balancing and for effective training the model. To further improve the predictive performance of model we used stacking technique. Among the three base classifiers (CNN, LSTM, GRU) the predictive performance of GRU are better as compared to individual model. The GRU is selected as a meta classifier to distinguish between Non-IDC and IDC breast images. The method Hold-Out has been incorporated and the data set is split into 90% and 10% for training and testing of the model, respectively. Model evaluation metrics have been computed for model performance evaluation. To analyze the efficacy of the model, we have used breast histology images data set. Our experimental results demonstrated that the proposed StackBC method achieved improved performance by gaining 99.02% accuracy and 100% area under the receiver operating characteristics curve (AUC-ROC) compared to state-of-the-art methods. Due to the high performance of the proposed method, we recommend it for early recognition of breast cancer in E-Healthcare.

scholarly journals Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial

2009 ◽  
Vol 27 (30) ◽  
pp. 4939-4947 ◽  
Author(s):  
Heather A. Jones ◽  
Ninja Antonini ◽  
Augustinus A.M. Hart ◽  
Johannes L. Peterse ◽  
Jean-Claude Horiot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Breast Conserving Therapy ◽  
Local Relapse ◽  
High Grade ◽  
Invasive Tumor ◽  
Boost Dose ◽  
Central Pathology ◽  
Pathology Review

Purpose To investigate the long-term impact of pathologic characteristics and an extra boost dose of 16 Gy on local relapse, for stage I and II invasive breast cancer patients treated with breast conserving therapy (BCT). Patients and Methods In the European Organisation for Research and Treatment of Cancer boost versus no boost trial, after whole breast irradiation, patients with microscopically complete excision of invasive tumor, were randomly assigned to receive or not an extra boost dose of 16 Gy. For a subset of 1,616 patients central pathology review was performed. Results The 10-year cumulative risk of local breast cancer relapse as a first event was not significantly influenced if the margin was scored negative, close or positive for invasive tumor or ductal carcinoma in situ according to central pathology review (log-rank P = .45 and P = .57, respectively). In multivariate analysis, high-grade invasive ductal carcinoma was associated with an increased risk of local relapse (P = .026; hazard ratio [HR], 1.67), as was age younger than 50 years (P < .0001; HR, 2.38). The boost dose of 16 Gy significantly reduced the local relapse rate (P = .0006; HR, 0.47). For patients younger than 50 years old and in patients with high grade invasive ductal carcinoma, the boost dose reduced the local relapse from 19.4% to 11.4% (P = .0046; HR, 0.51) and from 18.9% to 8.6% (P = .01; HR, 0.42), respectively. Conclusion Young age and high-grade invasive ductal cancer were the most important risk factors for local relapse, while margin status had no significant influence. A boost dose of 16 Gy significantly reduced the negative effects of both young age and high-grade invasive cancer.

scholarly journals 925 Utilizing multiplex immunofluorescence to explore the epithelial-mesenchymal transition in breast, ovarian cancers

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A970-A970
Author(s):  
Danielle Fails ◽  
Michael Spencer
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Poor Prognosis ◽  
Epithelial Mesenchymal Transition ◽  
Ductal Carcinoma ◽  
Beta Catenin ◽  
Mesenchymal Transition ◽  
Cell Counts ◽  
Grade Ii ◽  
E Cadherin

BackgroundEpithelial-mesenchymal transition (EMT) is instrumental during embryonic development—assisting in extensive movement and differentiation of cells. However, during metastasis and tumorigenesis, this process is hijacked. The disruption of this developmental process, and subsequent acquisition of a mesenchymal phenotype, has been shown to increase therapeutic resistance and often leads to poor prognosis in breast cancer.1 Using bioinformatic resources and current clinical data, we designed a panel of biomarkers of value to specifically observe this epithelial/mesenchymal transition.MethodsHuman breast cancer FFPE tissue samples were stained with Bethyl Laboratories IHC-validated primary antibodies, followed by Bethyl HRP-conjugated secondary antibodies, and detected using Akoya Opal™ Polaris 7-color IHC kit fluorophores (Akoya Biosciences [NEL861001KT]). The panel consisted of beta-Catenin, E-Cadherin, Ki67, CD3e, PD-L1, and FOXP3. Antibody staining order was optimized using tissue microarray serial sections, three slides per target, and stained in either the first, third, or sixth position via heat-induced epitope retrieval (HIER) methods. Exposure time was maintained for all three slides/target and cell counts, signal intensity, background, and autofluorescence were analyzed. The final optimized order was then tested on the breast cancer microarray in seven-color mIF. Whole slide scans were generated using the Vectra Polaris® and analyses performed using InForm® and R® Studio.ResultsTwo integral EMT targets, E-Cadherin and beta-Catenin, were used to observe a key occurrence in this transition. Under tumorigenic circumstances, when released from the complex they form together (E-cadherin-B-catenin complex), Beta-catenin can induce EMT. This disjunction/activation of EMT can be seen in the invasive ductal carcinoma below (figure 1).The disorganized E-cadherin cells are in direct contrast to normal, non-cancerous cells in similar tissue. Total CD3e cell counts were down (2%), with 35% cells restricted to the stroma vs. the 1% seen intra-tumorally. Coupled with the elevated presence of Ki67 (10%), a level of rapid cancer growth and potential metastasis (Invasive Ductal Carcinoma Grade II) can be observed.Abstract 925 Figure 1Invasive ductal carcinoma, grade II stained with a 6-plex mIF panel designed to show the epithelial-mesenchymal transitionConclusionsThe presence of EMT in breast cancers is often indicative of a poor prognosis, so the need for reliable markers is imperative. E-Cadherin and beta-Catenin are both up-and-coming clinical targets that can serve to outline this transition within the tumor microenvironment. By utilizing these markers in mIF, closer spatial examination of proteins of interest can be achieved. The application of this mIF panel has the potential to provide invaluable insights into how tumor infiltrating lymphocytes behave in cancers exhibiting the hallmarks of EMT.AcknowledgementsWe would like to acknowledge Clemens Deurrschmid, PhD, Technical Applications Scientist Southeast/South Central, Akoya Biosciences for his assistance with image analysis.ReferencesHorne HN, Oh H, Sherman ME, et al. E-cadherin breast tumor expression, risk factors and survival: pooled analysis of 5,933 cases from 12 studies in the breast cancer association consortium. Sci Rep 2018;8:6574.

scholarly journals Quantitative and dosimetric analysis for treating synchronous bilateral breast cancer using two radiotherapy planning techniques

2021 ◽  
Vol 27 (3) ◽  
pp. 201-206
Author(s):  
Özlem Mermut ◽  
Aysun Ozsoy Ata ◽  
Didem Can Trabulus
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Organs At Risk ◽  
Bilateral Breast Cancer ◽  
Radiotherapy Planning ◽  
Conformity Index ◽  
Treatment Unit ◽  
Significant Difference ◽  
Synchronous Bilateral Breast Cancer ◽  
The Right

Abstract Objective: We compared mono-isocenter and dual-isocenter plans in synchronous bilateral breast cancer (SBBC), which is defined as tumours occurring simultaneously in both breasts, and evaluated the effects of these differences in plans on organs-at-risk (OARs). Materials and methods: We evaluated 10 women with early stage, nod negative (Tis-2N0M0) SBBC. The treatment dose was determined to be 50 Gy. We used mean dose and VXGy to evaluate the OARs. To evaluate the effectiveness of treatment plans, Homogeneity index (HI), conformity index (CI) and sigma index (SI) and monitor units (MU) of monoisocenter (MIT) and dual-isocenter (DIT) plans were compared. During bilateral breast planning, for the single-centre plan, the isocenter was placed at the center of both breasts at a depth of 3-4 cm. For the two-center plan, dual-isocenters were placed on the right and left breasts. Results: No significant difference between the techniques in terms of the scope of the target volume was observed. Statistically significant results were not achieved in MIT and DIT plans for OARs. Upon comparing MIT and DIT, the right-side monitor unit (MU) value in DIT (p = 0.011) was statistically significantly lower than that in MIT. Upon comparing right-left side MIT and DIT, the MU value (p = 0.028) was significantly lower in DIT than MIT. Conclusion: SBBC irradiation is more complex than unilateral breast radiotherapy. No significant difference between both techniques and OARs was observed. However, we recommend MIT as a priority technique due to the ability to protect OARs, ease of administration during treatment, and the fact that the patient stays in the treatment unit for a shorter period of time.

Sign in / Sign up

Export Citation Format

Share Document